10-Q: Natural Alternatives International Faces Financial Covenant Breach

Natural Alternatives International Inc. reported a net loss of $2.48 million for the quarter ended September 30, 2026, and is in breach of a key financial covenant with its lender, Legacy Corporate Lending.

Summary

• Natural Alternatives International, Inc. (NAII) reported a net loss of $2.48 million for the three months ended September 30, 2026, compared to a net loss of $0.29 million in the same period last year.
• Net sales decreased by 25% to $28.12 million from $37.73 million in the prior year's quarter, primarily due to a 29% drop in private-label contract manufacturing sales.
• The company is in non-compliance with a fixed charge coverage ratio covenant with its lender, Legacy Corporate Lending, as of September 30, 2026, leading to the reclassification of $10.0 million in debt as current liabilities.
• Management is actively discussing a forbearance letter, waiver, or amendment with Legacy Corporate Lending, but there is no assurance of a favorable outcome.
• Substantial doubt exists regarding the company's ability to continue as a going concern, stemming from net losses, negative operating cash flows, and the covenant non-compliance.
• The company is exploring strategic alternatives, including mergers, acquisitions, joint ventures, or a sale, and is selling its Carlsbad, California headquarters.
• Patent and trademark licensing revenue increased by 54% to $2.6 million, driven by TriBsyn product sales, partially offsetting the decline in contract manufacturing.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as negative due to significant financial covenant non-compliance, a substantial net loss, and ongoing going concern doubts, despite some revenue growth in specific segments.

Positives

• Patent and trademark licensing revenue increased by 54% to $2.6 million for the three months ended September 30, 2026, compared to $1.7 million in the prior year.
• The company is actively pursuing strategic alternatives to maximize shareholder value, including potential mergers, acquisitions, joint ventures, or a sale.
• Management is implementing actions to address going concern doubts, including the sale of its corporate headquarters and consolidation of facilities.
• NAIE, the Swiss subsidiary, is in compliance with its credit agreement with UBS Switzerland AG and has CHF 2.0 million available under a new credit facility.

Negatives

• Reported a net loss of $2.48 million for the three months ended September 30, 2026, a significant increase from the $0.29 million loss in the prior year.
• Net sales decreased by 25% to $28.12 million, with private-label contract manufacturing sales down 29% due to decreased orders from key customers.
• Non-compliance with a critical financial covenant (fixed charge coverage ratio) with lender Legacy Corporate Lending as of September 30, 2026.
• Due to covenant non-compliance, $10.0 million of debt previously classified as long-term has been reclassified as current liabilities.
• Substantial doubt exists regarding the company's ability to continue as a going concern.
• Gross profit margin significantly decreased to 4.5% from 11.7% due to lower sales volume and reduced factory capacity utilization.
• Selling, general and administrative expenses as a percentage of net sales increased to 13.7% from 10.9%.

Risks

• Non-compliance with financial covenants under the Legacy Corporate Lending agreement, potentially leading to default and exercise of lender rights.
• The company's ability to continue as a going concern is in doubt due to ongoing net losses, negative operating cash flows, and covenant breaches.
• The loss of any of the company's major private-label contract manufacturing customers could have a material adverse impact.
• Reliance on a limited number of raw material suppliers for key ingredients like beta-alanine poses a risk if these suppliers are lost.
• Geopolitical uncertainties and potential economic effects from ongoing conflicts could impact raw material sourcing and global shipping.
• Future tariffs imposed by governments could adversely affect customers' businesses, the availability and cost of raw materials, and demand for products.
• The company's ability to maintain its patent and trademark licensing revenue depends on expanding market reach, maintaining patent rights, and raw material availability.
• The company is undergoing a comprehensive review of strategic alternatives, which could result in significant changes to its structure or ownership.

Future Outlook

The company anticipates an increase in net sales for fiscal year 2027 compared to fiscal year 2026 and expects to return to profitability in the fourth quarter of fiscal year 2027. Management is focused on leveraging facilities, expanding its beta-alanine patent and trademark estate, and consolidating operations to improve efficiencies and profitability.

Management Comments

• "We experienced a loss from operations during the first three months of fiscal 2027 primarily due to underutilization of our factory capacities."
• "The decrease in net sales was primarily related to a decline in private label contract manufacturing sales, partially offset by increased patent and trademark licensing sales which resulted in a decrease in gross profit and factory utilization."
• "Selling, general and administrative expenses decreased as compared to the prior year primarily related to a decrease in compensation expense associated with lower headcount, offset by an increase in costs incurred to prepare our corporate office for sale."
• "We currently anticipate we will experience an increase in net sales for fiscal 2027 as compared fiscal 2026 and return to profitability in our fourth quarter of fiscal 2027."

Industry Context

StockSavvy.ai notes that Natural Alternatives International operates in the competitive nutritional supplement and contract manufacturing space. The reported decline in private-label sales reflects broader industry pressures, potentially including shifts in consumer demand or increased competition. The growth in patent and trademark licensing, particularly with new products like TriBsyn and CarnoSyn 4X, highlights a strategic pivot towards higher-margin, intellectual property-driven revenue streams, which is a common strategy for companies seeking to differentiate and improve profitability in this sector.

Comparison to Industry Standards

• The gross profit margin of 4.5% for the contract manufacturing segment is significantly below typical industry benchmarks for contract manufacturers, which often range from 10-20%, indicating potential issues with pricing, cost control, or capacity utilization.
• The company's net loss and negative operating cash flows are concerning, especially when compared to industry peers who may be experiencing more stable or positive financial performance.
• The increase in patent and trademark licensing revenue (54%) is a positive sign, as companies in this sector often seek to leverage intellectual property for growth, but the overall revenue decline suggests challenges in the core contract manufacturing business.
• The company's focus on new product development (TriBsyn, CarnoSyn 4X) aligns with industry trends of innovation in the sports nutrition and wellness markets, aiming to capture higher-value segments.

Legal Proceedings

• Lawsuits filed by three former employees in December 2023 as a putative class action and California Private Attorney General Action seeking awards for similarly situated employees. A tentative settlement of $1.25 million was reached in July 2025, with payment remitted in Q1 FY2027 and final court approval expected in February 2027.

Stakeholder Impact

• Shareholders: Potential dilution from future capital raises or a sale of the company; risk of further share price decline due to financial distress and going concern issues.
• Creditors: Increased risk due to covenant non-compliance and potential default on the Legacy Corporate Lending facility.
• Employees: Potential impact from cost containment measures, headcount reductions, and the ongoing strategic review which could lead to restructuring or acquisition.
• Customers: Potential disruption if the company's financial instability affects supply chain reliability; however, the company aims to pass through material cost increases and identify alternative supply sources.
• Suppliers: Potential impact on payment terms or order volumes due to the company's financial situation and efforts to manage working capital.

Next Steps

• Continue discussions with Legacy Corporate Lending regarding covenant non-compliance.
• Execute plans to mitigate going concern doubts, including sale of corporate headquarters and facility consolidation.
• Continue sales and marketing efforts for CarnoSyn, SR CarnoSyn, CarnoSyn 4X, and TriBsyn beta-alanine products.
• Focus on expanding commercialization of beta-alanine patent and trademark estate.
• Consolidate facilities and factories to improve operational efficiencies and manage costs.
• Complete the sale of the Carlsbad, California powder processing and storage facility.
• Final court approval and termination of former employee lawsuits settlement expected in February 2027.

Key Dates

Recommendation

The company is facing significant financial headwinds, including a substantial net loss, declining revenues in its core business, and critical non-compliance with loan covenants. The going concern doubt, coupled with ongoing discussions with lenders that lack certainty, presents a high level of risk. While there are positive developments in the licensing segment and strategic reviews are underway, the immediate financial distress and covenant breach outweigh these factors, suggesting a sell recommendation.

Keywords

contract manufacturing, nutritional supplements, beta-alanine, licensing, financial covenant, going concern, revenue, net loss